Zura Bio Stock (NASDAQ:ZURA)

Forecast Revenue Ownership Financials Chart

Previous Close

$1.26

52W Range

$0.97 - $5.07

50D Avg

$1.21

200D Avg

$2.41

Market Cap

$75.49M

Avg Vol (3M)

$465.61K

Beta

-0.13

Div Yield

-

ZURA Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

30

IPO Date

Mar 21, 2023

Website

ZURA Performance

ZURA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-55.19M	$-62.64M	$-2.68M
Net Income	$-45.39M	$-60.36M	$3.55M
EBITDA	$-55.19M	$-60.56M	$-27.33M
Basic EPS	$-0.60	$-2.09	$0.21
Diluted EPS	$-0.60	$-2.09	$0.21

Fiscal year ends in Dec 24 | Currency in USD